Rallybio Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RLYB Nasdaq 2836 www.rallybio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Rallybio Corporation

VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development - Jun 24th, 2026 12:15 pm
Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing - Jun 22nd, 2026 9:40 am
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own? - Jun 1st, 2026 10:26 am
RallyBio tries again for reverse merger, this time with Avenzo - Jun 1st, 2026 9:03 am
Rallybio to acquire Candid Therapeutics - Mar 3rd, 2026 5:29 am
Candid, in a reverse merger with RallyBio, to go public - Mar 2nd, 2026 4:05 am
Stock Splits Matter: Notable Splits in 2025 and What’s Happening in 2026 - Feb 4th, 2026 8:05 am
Stock Splits Matter: What’s Coming Up This Month? - Feb 4th, 2026 8:05 am
Does Short Squeeze Attention and AI Advances Alter the Bull Case for Recursion Pharmaceuticals (RXRX)? - Sep 27th, 2025 7:49 am
Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances - Sep 21st, 2025 7:26 am
Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid - Aug 17th, 2025 4:16 pm
Rallybio First Half 2025 Earnings: US$0.43 loss per share (vs US$0.83 loss in 1H 2024) - Aug 9th, 2025 6:34 am